News | May 04, 2026
Bristol Myers Squibb begins 2026 with growth momentum
The company’s Growth Portfolio delivered $6.2 billion in revenue
The company’s Growth Portfolio delivered $6.2 billion in revenue
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
The company posted revenue of €1,267 million, up 6% on a constant currency basis
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
But acquisition charges drag earnings into loss
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
Study introduces structured, condition-specific emergency coding system to improve coordination, response time, and patient safety in tertiary care hospitals
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
Subscribe To Our Newsletter & Stay Updated
